ESMO 2014 Congress

Cabazitaxel in Patients with Renal Impairment

Madrid—Renal impairment had no clinically meaningful effect on the pharmacokinetic activity of cabazitaxel (Cbz). That was one of the findings of an open-label, multicenter study conducted recently. Study results were presented during a poster session at the EMSO 2014 Congress in Madrid. The poster was titled Pharmacokinetic Activity of Cabazitaxel in Patients with Renal Impairment. The study was designed to ... Read More »